212 related articles for article (PubMed ID: 20803231)
21. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.
Cheng H; Kari G; Dicker AP; Rodeck U; Koch WJ; Force T
Circ Res; 2011 Dec; 109(12):1401-9. PubMed ID: 21998323
[TBL] [Abstract][Full Text] [Related]
22. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
[TBL] [Abstract][Full Text] [Related]
23. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Wei G; Wang M; Hyslop T; Wang Z; Carr BI
Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
[TBL] [Abstract][Full Text] [Related]
24. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.
Panka DJ; Wang W; Atkins MB; Mier JW
Cancer Res; 2006 Feb; 66(3):1611-9. PubMed ID: 16452220
[TBL] [Abstract][Full Text] [Related]
25. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
Moreno-Vinasco L; Gomberg-Maitland M; Maitland ML; Desai AA; Singleton PA; Sammani S; Sam L; Liu Y; Husain AN; Lang RM; Ratain MJ; Lussier YA; Garcia JG
Physiol Genomics; 2008 Apr; 33(2):278-91. PubMed ID: 18303084
[TBL] [Abstract][Full Text] [Related]
26. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
27. The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.
Martin del Campo SE; Levine KM; Mundy-Bosse BL; Grignol VP; Fairchild ET; Campbell AR; Trikha P; Mace TA; Paul BK; Jaime-Ramirez AC; Markowitz J; Kondadasula SV; Guenterberg KD; McClory S; Karpa VI; Pan X; Olencki TE; Monk JP; Mortazavi A; Tridandapani S; Lesinski GB; Byrd JC; Caligiuri MA; Shah MH; Carson WE
J Immunol; 2015 Sep; 195(5):1995-2005. PubMed ID: 26238487
[TBL] [Abstract][Full Text] [Related]
28. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
[TBL] [Abstract][Full Text] [Related]
29. RAF kinase activity regulates neuroepithelial cell proliferation and neuronal progenitor cell differentiation during early inner ear development.
Magariños M; Aburto MR; Sánchez-Calderón H; Muñoz-Agudo C; Rapp UR; Varela-Nieto I
PLoS One; 2010 Dec; 5(12):e14435. PubMed ID: 21203386
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
[TBL] [Abstract][Full Text] [Related]
31. C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Jilaveanu LB; Zito CR; Aziz SA; Conrad PJ; Schmitz JC; Sznol M; Camp RL; Rimm DL; Kluger HM
Clin Cancer Res; 2009 Sep; 15(18):5704-13. PubMed ID: 19737955
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.
Plaza-Menacho I; Mologni L; Sala E; Gambacorti-Passerini C; Magee AI; Links TP; Hofstra RM; Barford D; Isacke CM
J Biol Chem; 2007 Oct; 282(40):29230-40. PubMed ID: 17664273
[TBL] [Abstract][Full Text] [Related]
33. Repurposing the clinically approved calcium antagonist manidipine dihydrochloride as a new early inhibitor of human cytomegalovirus targeting the Immediate-Early 2 (IE2) protein.
Mercorelli B; Luganini A; Celegato M; Palù G; Gribaudo G; Loregian A
Antiviral Res; 2018 Feb; 150():130-136. PubMed ID: 29274844
[TBL] [Abstract][Full Text] [Related]
34. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effect of 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H - imidazole on HCMV DNA replication and permissive infection.
Johnson RA; Huong SM; Huang ES
Antiviral Res; 1999 Apr; 41(3):101-11. PubMed ID: 10320043
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.
Ramakrishnan V; Timm M; Haug JL; Kimlinger TK; Halling T; Wellik LE; Witzig TE; Rajkumar SV; Adjei AA; Kumar S
Am J Hematol; 2012 Mar; 87(3):277-83. PubMed ID: 22190165
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
Nagai T; Arao T; Furuta K; Sakai K; Kudo K; Kaneda H; Tamura D; Aomatsu K; Kimura H; Fujita Y; Matsumoto K; Saijo N; Kudo M; Nishio K
Mol Cancer Ther; 2011 Jan; 10(1):169-77. PubMed ID: 21220499
[TBL] [Abstract][Full Text] [Related]
38. The multi-targeted kinase inhibitor sorafenib inhibits enterovirus 71 replication by regulating IRES-dependent translation of viral proteins.
Gao M; Duan H; Liu J; Zhang H; Wang X; Zhu M; Guo J; Zhao Z; Meng L; Peng Y
Antiviral Res; 2014 Jun; 106():80-5. PubMed ID: 24680956
[TBL] [Abstract][Full Text] [Related]
39. Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.
Eum KH; Ahn SK; Kang H; Lee M
Mol Cell Biochem; 2013 Jan; 372(1-2):65-74. PubMed ID: 22941213
[TBL] [Abstract][Full Text] [Related]
40. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Wilhelm SM; Carter C; Tang L; Wilkie D; McNabola A; Rong H; Chen C; Zhang X; Vincent P; McHugh M; Cao Y; Shujath J; Gawlak S; Eveleigh D; Rowley B; Liu L; Adnane L; Lynch M; Auclair D; Taylor I; Gedrich R; Voznesensky A; Riedl B; Post LE; Bollag G; Trail PA
Cancer Res; 2004 Oct; 64(19):7099-109. PubMed ID: 15466206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
